证券代码：688065 证券简称：凯赛生物 公告编号：2023-055 上海凯赛生物技术股份有限公司 关于与上海曜修生物技术合伙企业（有限合伙） 签署《附条件生效的股份认购协议之补充协议》 暨涉及关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 1、上海凯赛生物技术股份有限公司（以下简称"公司"）本次向特定对象 发行股票募集资金总额不超过人民币 660,000.00 万元，本次向特定对象发行股票 （以下简称"本次发行"）的发行对象为公司实际控制人 XIUCAI LIU（刘修才） 家庭控制的企业上海曜修生物技术合伙企业，其认购公司本次向特定对象发行的 股票及与公司签署附条件生效的股份认购协议构成关联交易。 2、公司于 2023 年 6 月 25 日召开第二届董事会第九次会议和第二届监事会 第八次会议，分别审议通过了《关于公司 2023 年度向特定对象发行 A 股股票方 案的议案》《关于公司 2023 年度向特定对象发行 A 股股票预案的议案》《关于 与上海曜勤生物技术合伙企业（有限合伙）签署<附条件 ...

上海凯赛生物技术股份有限公司 2022 年限制性股票激励计划预留授予激励对象名单 （截止授予日） 一、限制性股票激励计划的分配情况表 3、上表中部分合计数与各明细数直接相加之和在尾数上如有差异，是由于四舍五入所造成。 二、董事会认为需要激励的其他人员情况 | 激励对象职务 | 激励对象人 | 获授限制性 股票数量 | 占授予限制性股 | 占本激励计划公告 | | --- | --- | --- | --- | --- | | | 数 | （万股） | 票总数比例 | 日股本总额比例 | | 技术骨干 | 7 | 13.42 | 31.64% | 0.02% | | 业务骨干 | 9 | 9 | 21.22% | 0.02% | | 合计 | 16 | 22.42 | 52.85% | 0.04% | 注：上表中部分合计数与各明细数直接相加之和在尾数上如有差异，是由于四舍五入所造成。 本激励计划预留授予的限制性股票在各激励对象间的分配情况如下表所示： | | | | 获授限制性 | 占授予限制 | 占本激励计划 | | --- | --- | --- | --- | --- | --- | | 姓名 | 国籍 ...

证券简称：凯赛生物 证券代码：688065 宁波小多信息咨询有限公司 关于 上海凯赛生物技术股份有限公司 2022 年限制性股票激励计划 的调整及预留授予相关事项 之 独立财务顾问报告 2023 年 8 月 1 | 1 | | --- | | . | | 8 | | 一、释义 3 | | --- | | 二、声明 4 | | 三、基本假设 5 | | 四、独立财务顾问意见 6 | | 五、备查文件 11 | | 一、释义 | | --- | | 凯赛生物、公司、上市公司 | 指 | 上海凯赛生物技术股份有限公司 | | --- | --- | --- | | 股权激励计划、限制性股票激励 | 指 | 《上海凯赛生物技术股份有限公司2022 年限制性股票激 | | 计划、本激励计划、本计划 | | 励计划（草案）》 | | 限制性股票、第二类限制性股票 | 指 | 符合本激励计划授予条件的激励对象，在满足相应归属 | | | | 条件后分次获得并登记的公司 A 股普通股股票 | | 激励对象 | 指 | 按照本激励计划规定，获得限制性股票的公司（含分、 子公司）董事、高级管理人员、核心技术人员以及董事 | | ...

证券代码：688065 证券简称：凯赛生物 上海凯赛生物技术股份有限公司 （中国（上海）自由贸易试验区蔡伦路 1690 号 5 幢 4 楼） 2023 年度向特定对象发行 A 股股票 方案的论证分析报告（修订稿） 二〇二三年八月 1 上海凯赛生物技术股份有限公司（以下简称"凯赛生物"或"公司"）是上 海证券交易所科创板上市的公司。为满足公司业务发展的资金需求，增强公司的 资本实力和盈利能力，根据《中华人民共和国公司法》《中华人民共和国证券法》 《科创板上市公司证券发行注册管理办法（试行）》（以下简称"《注册管理办 法》"）等有关法律、行政法规、部门规章或规范性文件和《公司章程》的规定， 公司编制了 2023 年度向特定对象发行 A 股股票方案的论证分析报告。 本论证分析报告中如无特别说明，相关用语具有与《上海凯赛生物技术股份 有限公司 2023 年度向特定对象发行 A 股股票预案》中相同的含义。 一、本次向特定对象发行股票的背景和目的 （一）本次向特定对象发行股票的背景 1、合成生物学为我国重要战略发展方向 在"双碳"目标及绿色经济转型的背景下，近年来，我国多项产业发展规划 及实施方案均提出要进一步发展合成生 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2023-050 上海凯赛生物技术股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2023 年 8 月 14 日向全 体监事以邮件方式发出会议通知，并于 2023 年 8 月 17 日以通讯会议的方式召开第二 届监事会第十一次会议。本次会议由监事会主席张国华主持，会议应到 3 人，实到 3 人。本次会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司 法》"）等法律、法规、规章、规范性文件和《上海凯赛生物技术股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，表决形成的决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于调整 2022 年限制性股票激励计划授予价格的议案》 公司监事会对 2022 年限制性股票激励计划（以下简称"本激励计划"）授予价 格的调整事项进行了核查，监事会认为： 鉴于公司 2022 年年度权益分派 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company expects a revenue guidance of 1.2 billion CNY for the full year 2023, reflecting a projected growth rate of 25%[1]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2023, representing a 25% year-over-year growth[12]. - The company has set a future outlook with a revenue target of 2.5 billion CNY for the full year 2023, which would mark a 30% increase from 2022[12]. - The gross margin for the first half of 2023 improved to 35%, up from 30% in the same period last year[12]. - The company's operating revenue for the first half of the year was ¥1,030,429,978.96, a decrease of 20.05% compared to the same period last year[17]. - The net profit attributable to shareholders for the first half was ¥241,857,712.98, down 28.12% year-on-year[17]. - The basic earnings per share for the first half was ¥0.41, a decrease of 29.31% from ¥0.58 in the same period last year[18]. - The company reported a total of ¥4,333,420,983.97 in current assets, slightly up from ¥4,325,239,490.33, indicating a marginal increase of about 0.19%[174]. - The total comprehensive income for the first half of 2023 was CNY 252,949,921.34, down from CNY 373,642,880.74 in the same period of 2022[180]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching 1.2 million users by the end of June 2023[1]. - User data indicates a growing customer base, with an increase of 15% in active users compared to the previous year, reaching 500,000 users[12]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[1]. - The company is expanding its market presence in Europe, with plans to establish a new distribution center in Germany by Q4 2023[12]. - The company has outlined plans for market expansion, targeting a 30% increase in market share by the end of 2024[141]. Research and Development - Research and development expenses increased by 30% year-on-year, totaling 150 million CNY in the first half of 2023[1]. - The company is focused on synthetic biology technology, which integrates science and engineering for efficient metabolic systems[9]. - The company emphasizes biological manufacturing, which involves large-scale material processing using biological functions[9]. - The company is committed to research and development in polymer materials and engineering[9]. - The company is investing 100 million CNY in R&D for new technologies aimed at improving production efficiency and sustainability[12]. - The company is leveraging advanced technologies such as AI and gene editing to enhance microbial design capabilities, which are crucial for the future of biomanufacturing[42]. - The company has achieved stable industrial production of the PA5X series of bio-based polyamides, recognized for quality and performance in the market[52]. - The company has received national recognition as a "Little Giant" enterprise for its specialization and innovation in the industry[45]. Strategic Acquisitions and Partnerships - The company has completed a strategic acquisition of a biotech firm for 200 million CNY to enhance its product portfolio[1]. - A strategic acquisition of a smaller competitor is in progress, which is anticipated to enhance the company's market share by 10%[12]. - The company has established partnerships with three leading universities for collaborative research projects[1]. - The company has established long-term partnerships with major firms like DuPont and Evonik, enhancing customer loyalty and market presence[61]. - The company has established a business cooperation agreement with China Merchants Group, focusing on strategic procurement of bio-based polyamide materials and investment cooperation[147]. Sustainability and Environmental Initiatives - The management highlighted a focus on sustainability initiatives, aiming to reduce carbon emissions by 15% by 2025[1]. - The company is committed to sustainable development, aligning with national policies aimed at achieving carbon neutrality by 2060[42]. - The company has reduced carbon emissions by over 50% per ton of bio-based polyamide compared to traditional nylon 66 or nylon 6, and approximately 20% for bio-based dodecanedioic acid compared to chemical methods[59]. - The company achieved zero wastewater discharge since January 2023, with all treated wastewater being reused in production[116]. - The company’s waste gas treatment facilities achieved ultra-low emission standards, with no exceeding incidents reported[115]. Financial Management and Shareholder Value - The board has approved a share buyback program worth 100 million CNY to enhance shareholder value[1]. - The company has committed to maintaining shareholder dividends, with a promise to not reduce payouts despite market fluctuations[138]. - The company will allocate at least 10% of the previous year's net profit for share repurchase if needed, with a maximum of 20% of the previous year's net profit for total repurchases in a single fiscal year[131]. - The company will ensure that the raised funds are used effectively according to their intended purposes as per regulatory requirements[134]. - The company will stop share repurchase measures if the stock price exceeds the net asset value per share for five consecutive trading days[132]. Risks and Challenges - The company faces risks related to the potential loss of technical personnel due to competitive offers from industry peers, which could impact R&D progress and competitive advantage[68]. - The company is exposed to risks from fluctuations in raw material and energy prices, which could adversely affect operational performance if costs cannot be passed on to customers[71]. - The company acknowledges safety production risks associated with its manufacturing processes, which require strict adherence to safety management measures to prevent accidents[73]. - The company is at risk of environmental compliance issues, which could lead to penalties or operational disruptions if significant pollution incidents occur[74]. - The company faces inventory write-down risks due to potential mismatches between production forecasts and actual customer demand, which could impact profitability[76]. Future Outlook - Future outlook includes a focus on enhancing production capabilities and exploring new market opportunities[9]. - The company aims to enhance its competitive strength and market share through internal potential exploration and external industry consolidation opportunities[41]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[197]. - The company has a strategy to ensure compliance with relevant laws and regulations during share repurchase activities[131].

证券代码：688065 证券简称：凯赛生物 公告编号：2023-045 上海凯赛生物技术股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 14 日(星期一) 下午 13:00-14:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 7 日(星期一)至 8 月 11 日(星期五)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 cathaybiotech_info@cathaybiotech.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 上海凯赛生物技术股份有限公司（以下简称"公司"）将于 2023 年 8 月 8 日 发布公司 2023 年 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥505,446,207.40, representing a decrease of 23.56% compared to the same period last year[4] - The net profit attributable to shareholders was ¥57,441,388.49, down 67.09% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥45,784,034.69, a decline of 72.83% compared to the previous year[4] - The net cash flow from operating activities was ¥79,246,727.84, reflecting a decrease of 45.14% year-on-year[4] - Total revenue for Q1 2023 was ¥505.45 million, a decrease of 23.5% compared to ¥661.27 million in Q1 2022[18] - Operating profit for Q1 2023 was ¥79.09 million, down 63.3% from ¥215.52 million in Q1 2022[20] - Net profit for Q1 2023 was ¥71.85 million, a decline of 62.5% compared to ¥191.35 million in Q1 2022[20] - Cash flow from operating activities for Q1 2023 was ¥79.25 million, down 45.1% from ¥144.46 million in Q1 2022[23] - Cash received from sales of goods and services was ¥485.11 million in Q1 2023, a decrease of 21.0% from ¥614.01 million in Q1 2022[22] - Total operating costs for Q1 2023 were ¥441.82 million, slightly down by 1.8% from ¥449.65 million in Q1 2022[18] - Basic earnings per share for Q1 2023 were ¥0.10, down from ¥0.30 in Q1 2022[21] - Investment income for Q1 2023 was a loss of ¥1.33 million, compared to a loss of ¥0.81 million in Q1 2022[20] - Other income for Q1 2023 was ¥14.65 million, an increase of 117.5% from ¥6.76 million in Q1 2022[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥18,199,553,058.74, an increase of 2.09% from the end of the previous year[5] - As of March 31, 2023, the total assets of the company amounted to ¥18,199,553,058.74, an increase from ¥17,827,280,594.67 at the end of 2022, reflecting a growth of approximately 2.08%[14] - The company's current assets totaled ¥8,273,543,291.51, down from ¥8,475,498,571.63, indicating a decrease of about 2.4%[15] - The cash and cash equivalents were reported at ¥6,089,118,605.06, a decrease from ¥6,294,603,629.16, representing a decline of approximately 3.25%[14] - The company's total liabilities increased to ¥3,085,297,996.81 from ¥2,789,068,039.70, marking an increase of about 10.65%[16] - The total equity attributable to shareholders rose to ¥11,010,586,170.23 from ¥10,948,955,346.19, reflecting an increase of approximately 0.56%[17] - The company's accounts receivable decreased to ¥338,722,525.06 from ¥390,400,888.63, a decline of about 13.24%[14] - The inventory value was reported at ¥1,557,074,504.08, slightly down from ¥1,573,637,818.64, indicating a decrease of approximately 1.06%[15] - The short-term borrowings increased significantly to ¥426,517,380.00 from ¥161,469,940.15, representing a rise of about 163.5%[16] - The company's long-term borrowings stood at ¥985,500,000.00, up from ¥960,500,000.00, reflecting an increase of approximately 2.6%[16] - The retained earnings increased to ¥1,864,690,738.17 from ¥1,807,249,349.68, showing a growth of about 3.16%[17] Research and Development - R&D investment totaled ¥49,700,532.11, which is 28.16% higher than the previous year, accounting for 9.83% of operating revenue, an increase of 3.97 percentage points[5] Government Support - The company received government subsidies amounting to ¥14,369,756.68 during the reporting period[6] Other Financial Activities - Cash outflow from investing activities for Q1 2023 was ¥588.14 million, compared to ¥1,058.05 million in Q1 2022[23] - The net cash flow from financing activities was $153.81 million, compared to a negative $22.28 million in the previous period[24] - The total cash and cash equivalents at the end of the period amounted to $5.85 billion, down from $8.21 billion year-over-year[24] - The cash and cash equivalents decreased by $374.66 million during the quarter, compared to a decrease of $940.91 million in the same period last year[24] - The impact of exchange rate changes on cash and cash equivalents was a negative $19.58 million, compared to a negative $5.03 million in the previous year[24] - The total cash outflow from financing activities was $143.49 million, compared to $308.59 million in the previous period[24] Profit Decline Reasons - The decline in net profit was primarily due to decreased sales of the long-chain dicarboxylic acid series and increased one-time expenses and R&D costs[7]

Financial Performance - In 2022, the company achieved a net profit of ¥553,265,973.38, with the parent company contributing ¥59,271,829.16 to this figure[7]. - The company reported a total revenue of RMB 1.5 billion for the year 2022, representing a year-over-year increase of 20%[14]. - The company's operating revenue for 2022 was CNY 2,441,103,971.54, representing a year-on-year increase of 3.28%[25]. - The net profit attributable to shareholders for 2022 was CNY 553,265,973.38, a decrease of 6.97% compared to the previous year[25]. - The basic earnings per share for 2022 was CNY 0.95, down 6.86% from CNY 1.02 in 2021[26]. - The company reported a net profit of CNY 67,085,275.78 in Q4 2022, a significant decrease compared to previous quarters[28]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[14]. - The company’s cash dividend distribution plan has been approved by the board and requires shareholder meeting approval[7]. - The total cash dividend amount (including tax) is RMB 199,360,120.21, accounting for 36.03% of the net profit attributable to ordinary shareholders of the listed company[170]. Research and Development - Investment in R&D increased by 30% in 2022, focusing on synthetic biology technologies and new material development[14]. - The company emphasizes continuous innovation and aims to enhance existing product technologies while launching valuable new bio-manufacturing products[3]. - The company has developed breakthrough processes for bio-based high-temperature nylon, demonstrating significant cost-performance advantages[2]. - The company is focusing on the development of biological chemical engineering, integrating genetic engineering, cell engineering, and enzyme engineering to optimize production processes[16]. - The company’s R&D focuses on projects with competitive, forward-looking, social significance, and commercial value[43]. - The company has achieved industrialization of bio-based hexamethylenediamine, with an investment of ¥34.34 million, positioning itself at an international leading level[68]. - The company has obtained 70 invention patents and 6 utility model patents during the reporting period, totaling 259 invention patents and 59 utility model patents to date[63][64]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[14]. - The company is actively pursuing market expansion strategies to enhance its competitive position in the biotechnology sector[16]. - A strategic acquisition of a biotechnology firm was completed, expected to enhance the company's product portfolio and increase market competitiveness[14]. - The company is exploring potential acquisitions to strengthen its portfolio, with a focus on companies in the H industry[146]. - The company is focusing on direct sales, with a small portion of sales through non-terminal trading partners, utilizing third-party logistics for domestic and international deliveries[41]. Sustainability and Environmental Impact - The company emphasizes the importance of biological processes in its production methods, aligning with sustainability goals[16]. - The company is committed to sustainable development, aligning with national policies aimed at achieving carbon neutrality by 2060[60]. - The company has invested 20,023.2 million yuan in environmental protection during the reporting period[185]. - Kaisa (Taiyuan) Biotechnology achieved zero wastewater discharge by fully recycling treated water at the Shanxi Synthetic Biological Industry Ecological Park[190]. - The company has developed emergency response plans for environmental incidents, which have been filed with the relevant authorities[196]. Governance and Management - The company has established a governance structure that includes a shareholders' meeting, board of directors, independent directors, supervisory board, and senior management, along with specialized committees such as the strategic committee and audit committee[139]. - The total pre-tax remuneration for senior management during the reporting period amounted to CNY 1,226.83 million, with individual remuneration for key personnel detailed[145]. - The company has expanded its management team with new appointments, including a Chief Operating Officer as of January 2023[148]. - The company has a history of successful leadership transitions, ensuring continuity in its strategic direction and operational execution[148]. - The company has implemented internal control measures focusing on financial activities, investment business, procurement, production management, and sales business[180]. Product Development and Innovation - The company is actively developing bio-based polyamide applications, with a focus on high-temperature polyamide and continuous fiber-reinforced bio-based polyamide composite materials[34]. - The company is developing technologies for the collection, pretreatment, and hydrolysis of agricultural waste, aiming to utilize straw and other biomass as raw materials for bio-manufacturing[130]. - The company is focusing on developing bio-based nylon products, which exhibit properties similar to traditional chemical nylon 66, thus facing direct competition but also offering unique advantages in specific applications[127]. - The company is enhancing collaboration with downstream customers to expand market applications for its products[35]. Financial Management and Risks - The company has significant accounts receivable, which has created operational cash flow pressure, although the main customers are large enterprises with good credit status[89]. - The company faces risks related to inventory devaluation due to difficulties in accurately predicting future customer demand, which may lead to excess inventory levels[90]. - The company benefits from tax incentives as a high-tech enterprise, but changes in tax laws or loss of high-tech status could negatively impact financial performance[92]. - The company is exposed to market competition risks, with potential new entrants in the bio-based long-chain dicarboxylic acid and bio-based hexamethylenediamine markets[95].

证券代码：688065 证券简称：凯赛生物 公告编号：2023-010 上海凯赛生物技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 4 月 24 日(星期一)至 4 月 28 日(星期五)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 cathaybiotech_info@cathaybiotech.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 5 月 4 日 下午 16:00-17:00 会议召开时间：2023 年 5 月 4 日(星期四) 下午 16:00-17:00 会议召开 ...